Please login to the form below

Not currently logged in
Email:
Password:

Boehringer signs renal disease research collaboration

Will work with Hydra Biosciences to identify small-molecule TRP inhibitors

Boehringer Ingelheim headquarters 

Boehringer Ingelheim has signed a new research collaboration with Hydra Biosciences that will this time focus on renal diseases and disorders.

It will work with the Cambridge, US-based firm, which has a focus on transient receptor potential (TRP) channel modulation, on identifying small-molecule TRP inhibitors.

Dr Michel Pairet, senior corporate VP of research and non-clinical development at Boehringer, said: “This new collaboration agreement with Hydra Biosciences reflects the importance and value Boehringer Ingelheim places in developing strong research partners to discover new treatments for renal disease and related disorders.

The partnership marks the second collaboration between the two companies after they began to research and develop small molecule TRPC4/5 inhibitors for the treatment of central nervous system (CNS) diseases and disorders last year.

Under the terms of the agreement, Boehringer is responsible for the global development and commercialisation of the inhibitors that come from the collaboration and Hydra will receive an undisclosed upfront payment, additional research funding and will be eligible to receive milestone payments.

Russell Herndon, president and CEO of Hydra Biosciences, said: “This partnership between Boehringer Ingelheim and Hydra Biosciences provides an excellent opportunity to maximise the potential of novel targets that may offer meaningful improvements in the treatment of chronic kidney diseases and other related diseases and disorders. 

“Boehringer Ingelheim's long track record of research, development and commercialisation success makes them the perfect partner for this programme.”

Article by
Kirstie Pickering

15th April 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics